Skip to main content

Advertisement

Log in

Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to develop a Japanese version of hand-foot syndrome (HFS)-specific quality of life (QOL) questionnaire (HFS-14) to evaluate and monitor the QOL of patients with a possibility of HFS.

Methods

The original English version of HFS-14 was translated and slightly modified into Japanese, and the Japanese HFS-14 was administered to 187 patients receiving chemotherapy with high risk of developing HFS as outpatients in four institutions in Japan. Factor validity, internal consistency, correlation with the Skindex-16 and Dermatology Life Quality Index (DLQI) scores, known group validity, and test-retest reliability were analyzed for 105 patients who developed HFS. Next, we compared HFS-14 with DLQI and Skindex-16.

Results

Factor analysis confirmed the factor structure (one putative scale) of the Japanese HFS-14. Cronbach’s alpha was over 0.90. The Japanese HFS-14 score was correlated with the Skindex-16 and DLQI score. Intra-class correlation coefficients were over 0.80. Patients with severe HFS reported significantly poorer HFS-14 score than those with mild HFS. The Skindex-16 and DLQI scores were also significantly different in patients with different Common Terminology Criteria for Adverse Events (CTCAE) grades, but with smaller effect sizes than those for the HFS-14 score.

Conclusions

The Japanese HFS-14 provides a valid and reliable score for monitoring and evaluating HFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2011) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm). Accessed 11 Sep 2013

  2. Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T (2006) Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. Jpn J Clin Oncol 36:768–774

    Article  PubMed  Google Scholar 

  3. Hyodo I, Shirao K, Doi T et al (2006) A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 36:410–417

    Article  PubMed  Google Scholar 

  4. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696–2704

    Article  CAS  PubMed  Google Scholar 

  5. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299–305

    Article  PubMed  Google Scholar 

  6. Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166–1172

    Article  PubMed  Google Scholar 

  7. Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 31:1078–1086

    Article  CAS  PubMed  Google Scholar 

  8. Nardone B, Hensley JR, Kulik L et al (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11:e61–e65

    PubMed  Google Scholar 

  9. Rivera E, Valero V, Syrewicz L et al (2001) Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716–1722

    CAS  PubMed  Google Scholar 

  10. Shahrokni A, Rajebi MR, Saif MW (2009) Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma? Clin Colorectal Cancer 8:231–234

    Article  CAS  PubMed  Google Scholar 

  11. Park YH, Ryoo BY, Lee HJ, Kim SA, Chung JH (2003) High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Ann Oncol 14:1691–1692

    Article  CAS  PubMed  Google Scholar 

  12. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12:131–141

    Article  CAS  PubMed  Google Scholar 

  13. Azuma Y, Hata K, Sai K et al (2012) Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull 35:717–724

    Article  CAS  PubMed  Google Scholar 

  14. von Gruenigen V, Frasure H, Fusco N et al (2010) A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116:4735–4743

    Article  Google Scholar 

  15. Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469–1478

    Article  PubMed Central  PubMed  Google Scholar 

  16. Blanco-Aparicio M, Vazquez I, Pita-Fernandez S, Pertega-Diaz S, Verea-Hernando H (2013) Utility of brief questionnaires of health-related quality of life (Airways Questionnaire 20 and Clinical COPD Questionnaire) to predict exacerbations in patients with asthma and COPD. Health Qual Life Outcomes 11:85

    Article  PubMed Central  PubMed  Google Scholar 

  17. Delate T, Coons SJ (2001) The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis 32:E47–E52

    Article  CAS  PubMed  Google Scholar 

  18. Feyers D MD, ed. (2009) Quality of life: assessment, analysis and interpretation (second edition). John Wiley and sons, New York

  19. Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM (2002) The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol 29:693–698

    Article  PubMed  Google Scholar 

  20. Takahashi N, Suzukamo Y, Nakamura M et al (2006) Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 4:46

    Article  PubMed Central  PubMed  Google Scholar 

  21. Gerbrecht BM, Kangas T (2004) Implications of capecitabine (Xeloda) for cancer nursing practice. Eur J Oncol Nurs 8(Suppl 1):S63–S71

    Article  PubMed  Google Scholar 

  22. Cohen J (1992) A power primer. Psychol Bull 112:155–159

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a Third Term Comprehensive Control Research for Cancer fund from the Japanese Ministry of Health, Labour and Welfare [grant number 22092401]. The authors thank all the patients who took part in the study. The authors also thank Hiroyasu Esumi for his support.

Conflict of interest

The authors did not have any potential conflicts of interest in the research reported.

Financial support

This study was supported by a research group funded by the Ministry of Health, Labour and Welfare, Japan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naoko Mikoshiba.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mikoshiba, N., Yamamoto-Mitani, N., Sato, K. et al. Validation of the Japanese version of HFS-14, a disease-specific quality of life scale for patients suffering from hand-foot syndrome. Support Care Cancer 23, 2739–2745 (2015). https://doi.org/10.1007/s00520-015-2638-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2638-4

Keywords

Navigation